PT - JOURNAL ARTICLE AU - Soares, Ruben R. G. AU - Akhtar, Ahmad S. AU - Pinto, Inês F. AU - Lapins, Noa AU - Barrett, Donal AU - Sandh, Gustaf AU - Yin, Xiushan AU - Pelechano, Vicent AU - Russom, Aman TI - Point-of-care detection of SARS-CoV-2 in nasopharyngeal swab samples using an integrated smartphone-based centrifugal microfluidic platform AID - 10.1101/2020.11.04.20225888 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.04.20225888 4099 - http://medrxiv.org/content/early/2020/11/06/2020.11.04.20225888.short 4100 - http://medrxiv.org/content/early/2020/11/06/2020.11.04.20225888.full AB - With its origin estimated around December 2019 in Wuhan, China, the ongoing 2020 SARS-CoV-2 pandemic is a major global health challenge, resulting in more than 45 million infections and 1.2 million deaths. The demand for scalable, rapid and sensitive viral diagnostics is thus particularly pressing at present to help contain the rapid spread of infection and prevent overwhelming the capacity of health systems. While high-income countries have managed to rapidly expand diagnostic capacities, such is not the case in resource-limited settings of low- to medium-income countries.Aiming at developing cost-effective viral load detection systems for point-of-care COVID-19 diagnostics in resource-limited and resource-rich settings alike, we report the development of an integrated modular centrifugal microfluidic platform to perform loop-mediated isothermal amplification (LAMP) of viral RNA directly from heat-inactivated nasopharyngeal swab samples. The discs were pre-packed with dried n-benzyl-n-methylethanolamine modified agarose beads used as a versatile post-nucleic acid amplification signal enhancement strategy, allowing fluorescence detection via a smartphone camera and simple optics. The platform provided sample-to-answer analysis within 1 hour from sample collection and a detection limit between 100 and 1000 RNA copies in 10 μL reaction volume. Furthermore, direct detection of non-extracted SARS-CoV-2 RNA in nasopharyngeal swab samples from patients with Ct values below 26 (n=25 plus 6 PCR negative samples) was achieved with ∼94% sensitivity and 100% specificity, thus being fit-for-purpose to diagnose patients with a high risk of viral transmission. These results show significant promise towards bringing routine point-of-care COVID-19 diagnostics closer to resource-limited settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been sponsored in part by the European Union Horizon 2020 research and innovation programme New Diagnostics for Infectious Diseases (ND4ID) under the Marie Skłodowska-Curie grant agreement No. 675412. VP is supported by a SciLifeLab/KAW national COVID-19 research program project grant (KAW 2020.0182), Yin is supported by Ganzhou COVID-19 Emergency Research Project, Key Special Project of Technology Boosts Economy 2020 of Ministry of Science and Technology (SQ2020YFF0411358) for COVID-19 related work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained nasopharyngeal samples from Karolinska University Hospital, Huddinge (Stockholm) collected between May 20th and June 1st 2020. Samples were collected either using Sigma-Transwab or Sigma-Virocult kits (MWE, UK). We used pseudo-anonymized surplus material previously collected for clinical diagnostics of SARS-CoV-2. This is in accordance with the Swedish Act concerning the Ethical Review of Research Involving Humans, which allows development and improvement of diagnostic assays using patient samples which were collected to perform the testing in question. Additional ethical approval for RT-LAMP diagnosis was obtained by the appropriate Swedish Authority (Dnr 2020-01945, Etikproevningsnaemnden).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.